Immunome (NASDAQ:IMNM) Director Sells $397,362.88 in Stock

Posted by Brian Himes on Aug 13th, 2026

Immunome, Inc. (NASDAQ:IMNM – Get Free Report) Director Isaac Barchas sold 15,248 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $26.06, for a total transaction of $397,362.88. Following the completion of the transaction, the director directly owned 72,416 shares in the company, valued at $1,887,160.96. This represents a 17.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

On Wednesday, August 12th, Isaac Barchas sold 11,048 shares of Immunome stock. The stock was sold at an average price of $27.25, for a total value of $301,058.00.
On Tuesday, August 11th, Isaac Barchas sold 62,291 shares of Immunome stock. The stock was sold at an average price of $26.23, for a total value of $1,633,892.93.
On Monday, August 10th, Isaac Barchas sold 10,125 shares of Immunome stock. The shares were sold at an average price of $26.07, for a total value of $263,958.75.
On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total value of $543,090.40.
On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The stock was sold at an average price of $24.20, for a total value of $409,125.20.
On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The stock was sold at an average price of $24.11, for a total value of $2,003,396.34.
On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total value of $2,259,000.00.
On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The shares were sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Stock Up 6.6%

Shares of IMNM opened at $27.99 on Thursday. Immunome, Inc. has a 52-week low of $8.66 and a 52-week high of $28.04. The stock has a market cap of $3.17 billion, a PE ratio of -11.06 and a beta of 2.08. The firm’s fifty day moving average is $21.89 and its two-hundred day moving average is $22.20.

Immunome (NASDAQ:IMNM – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). As a group, research analysts anticipate that Immunome, Inc. will post -2.06 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Leerink Partners dropped their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday, May 15th. Barclays initiated coverage on shares of Immunome in a research report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price objective for the company. Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Finally, Wedbush increased their price target on shares of Immunome from $31.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Immunome has an average rating of “Moderate Buy” and an average target price of $34.64.

View Our Latest Report on Immunome

Hedge Funds Weigh In On Immunome

Large investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Immunome by 44.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock worth $316,000 after purchasing an additional 14,398 shares during the last quarter. Creative Planning acquired a new position in Immunome in the second quarter valued at about $167,000. Rhumbline Advisers lifted its position in Immunome by 22.0% in the second quarter. Rhumbline Advisers now owns 108,414 shares of the company’s stock valued at $1,008,000 after buying an additional 19,526 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Immunome by 3.6% during the second quarter. The Manufacturers Life Insurance Company now owns 280,816 shares of the company’s stock worth $2,612,000 after buying an additional 9,686 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Immunome during the second quarter valued at about $1,021,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

More Immunome News

Here are the key news stories impacting Immunome this week:

Positive Sentiment: Truist raised its price target to $38 from $37 and maintained a “Buy” rating, implying substantial additional upside from recent levels. The upgraded outlook likely provided the strongest near-term support for Immunome (IMNM). Benzinga analyst price target update
Positive Sentiment: Immunome reported its second-quarter 2026 results and provided a business update. Investors are likely focused on progress in the company’s clinical-stage antibody programs and its development pipeline, which remain key drivers of the stock’s valuation. Immunome second-quarter 2026 results and business update
Neutral Sentiment: Director Isaac Barchas sold a combined 98,712 shares from August 10 through August 12 for approximately $2.6 million. The sales reduced his direct ownership to 92,211 shares, but each transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which may make the activity less indicative of a change in his outlook. The transactions were disclosed in SEC filings. Immunome director insider sales SEC filing
Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, missing the consensus estimate of a $0.51 loss. The larger-than-expected loss underscores the company’s ongoing cash-burn and execution risks typical of a clinical-stage biotechnology company. Immunome quarterly earnings release

About Immunome

(Get Free Report)

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.